StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Reaktion

1,2-Dichloroethane → 1-9H-fluoren-9-ylmethyl (2R,3S)-4-(3,5-difluorophenyl)-2-hydroxy-3-{[5-oxo-5-(1-piperidinyl)pentanoyl]amino}butyl(3-iodobenzyl)carbamate

HRID 1783227
Drucken

Reaktionsgleichung

Reaktionsgleichung von HRID 1783227
C1C=CC2N(O)N=NC=2C=1.C(Cl)CCl.NC(C1C=[C:20]([CH:24]=[C:25]([C:27]([N:29]([CH2:33][CH2:34][CH3:35])[CH2:30][CH2:31]C)=[O:28])C=1)[C:21]([OH:23])=O)=O.Cl.[NH2:37][C@@H:38]([CH2:68][C:69]1[CH:74]=[C:73]([F:75])[CH:72]=[C:71]([F:76])[CH:70]=1)[C@H:39]([OH:67])[CH2:40][N:41]([CH2:59][C:60]1[CH:65]=[CH:64][CH:63]=[C:62]([I:66])[CH:61]=1)[C:42](=[O:58])[O:43][CH2:44][CH:45]1[C:57]2[CH:56]=[CH:55][CH:54]=[CH:53][C:52]=2[C:51]2[C:46]1=[CH:47][CH:48]=[CH:49][CH:50]=2.CN1CCOCC1>CN(C=O)C>[F:76][C:71]1[CH:70]=[C:69]([CH2:68][C@H:38]([NH:37][C:21](=[O:23])[CH2:20][CH2:24][CH2:25][C:27](=[O:28])[N:29]2[CH2:30][CH2:31][CH2:35][CH2:34][CH2:33]2)[C@H:39]([OH:67])[CH2:40][N:41]([CH2:59][C:60]2[CH:65]=[CH:64][CH:63]=[C:62]([I:66])[CH:61]=2)[C:42](=[O:58])[O:43][CH2:44][CH:45]2[C:46]3[CH:47]=[CH:48][CH:49]=[CH:50][C:51]=3[C:52]3[C:57]2=[CH:56][CH:55]=[CH:54][CH:53]=3)[CH:74]=[C:73]([F:75])[CH:72]=1
KomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion

Komponenten

7

Edukt 5

HCID 111,2-DichloroethaneHCID 79724-MethylmorpholineHCID 757711-HydroxybenzotriazoleHCID 223948913-Carbamoyl-5-dipropylcarbamoyl-benzoic acidHCID 865858561-9H-fluoren-9-ylmethyl(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl(3-iodobenzyl)carbamate hydrochloride

Produkt 1

HCID 58759852
1-9H-fluoren-9-ylmethyl (2R,3S)-4-(3,5-difluorophenyl)-2-hydroxy-3-{[5-oxo-5-(1-piperidinyl)pentanoyl]amino}butyl(3-iodobenzyl)carbamate

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 6228DimethylformamideLösungsmittel

Versuchsvorschrift

HOBt (81 mg, 0.6 mmole) and EDC (105 mg, 0.55 mmole) are added to 1-carboxy-5-piperdinylglutaramide (IX, 100 mg, 0.5 mmole) in DMF (2 ml). The acid is activated 60 minutes then treated with 1-9H-fluoren-9-ylmethyl (2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl(3-iodobenzyl)carbamate hydrochloride (XXXV, EXAMPLE 590, 300 mg, 0.43 mmole) and NMM (0.19 ml, 1.72 mmole). The reaction is stirred 3 hours then concentrated under reduced pressure. The residue is partitioned between ethyl acetate and saturated aqueous bicarbonate. The organic phases are washed with aqueous potassium bisulfate, saline, dried over sodium sulfate and finally concentrated under reduced pressure to give crude product. Purification via flash chromatography with ethyl acetate/hexane (50/50) then methanol/ethyl acetate (10/90) gives the title compound, M+H=838.

Aufarbeitung

  1. concentrationthen concentrated under reduced pressure
  2. customThe residue is partitioned between ethyl acetate and saturated aqueous bicarbonate
  3. washThe organic phases are washed with aqueous potassium bisulfate, saline
  4. dry with materialdried over sodium sulfate
  5. concentrationfinally concentrated under reduced pressure
  6. customto give crude product
  7. customPurification via flash chromatography with ethyl acetate/hexane (50/50)

Quellen und Nachweise

ORD-Eintrag
ord-d8c978de386f45d793555bdd7d820963
Quelldatensatz
uspto-grants-2009_03
DOI
10.6084/m9.figshare.5104873.v1
Patentnummer
US07498436B2

Notizen zur Reaktion

Auf dieser SeiteKomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion